Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 6.19% Upside As of July ...

Under Target's current policy, the company will match the price of store-bought products if customers "then find the ...

CWM LLC has more than doubled its stake in Regeneron Pharmaceuticals, snapping up an additional 2,007 shares to now hold a ...